HONG KONG, Nov. 14, 2025 (GLOBE NEWSWIRE) — Oriental Culture Holding LTD. (“OCG” or the “Company”) (NASDAQ: OCG), an online provider of collectibles and artwork e-commerce services, today announced its unaudited financial results for the six months ended June 30, 2025. First Half Year of 2025 Financial HighlightsTotal revenues were approximately $0.1 million for the six months ended June 30, 2025, compared with the total revenues of approximately $0.4 million for the six months ended June 30, 2024.Gross profit was approximately $0.1 million for the six months ended June 30, 2025, compared with approximately gross profit of $0.3 million for the six months ended June 30, 2024.Gross margin was 84.7% for the six months ended June 30, 2025, compared with a gross margin of 65.8% for the six months ended June 30, 2024.Loss from...

Revenue of $2.8 Million for Q3 2025, up 163% from Q3 2024 Gross Profit of $2.3 Million for Q3 2025, a 213% increase from Q3 2024; Gross Margin Expanded to 81.7% in Q3 2025, a 1,302 BPS Increase Management to Host Third Quarter 2025 Results Conference Call Today, Friday, November 14, 2025 at 4:30 p.m. Eastern Time SEATTLE, Nov. 14, 2025 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 and Subsequent Key Financial & Operational HighlightsRevenue of $2.8 million for Q3 2025, representing an increase of 163% over Q3 2024. Gross profit of $2.3 million for Q3 2025, representing an increase of 213%...

FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular and Cortical Bone Indices, Highlighted at NAMS and ASBMR Next-Generation EB613 Remains on Track for Phase 1 Initiation in Late 2025 Pre-Clinical Data for Oral OXM in Obesity and Oral GLP-2 in Short Bowel Syndrome in Collaboration with OPKO Presented at ENDO2025 and ESPEN JERUSALEM, Nov. 14, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended September 30, 2025. “Our achievements this quarter are testament to Entera’s leadership...

ST. LOUIS, Nov. 14, 2025 (GLOBE NEWSWIRE) — The Marketing Alliance, Inc. (OTC: MAAL) (“TMA” or the “Company”), announced its financial results today for its fiscal 2026 second quarter ended September 30, 2025. Q2 2026 Financial Key Items (all comparisons to the prior year quarter)Revenues from operations were $4,668,836 compared to $4,983,950, a decrease of over 6% which was almost entirely in the construction business Operating income from continuing operations of $149,507 compared to $486,639 in the prior year quarter Net income was $263,407 or $0.04 per share in the quarter compared to $401,511 or $0.05 per share in the prior year quarter During the quarter the Company repurchased 166,146 shares, and subsequent to the end of quarter the Company repurchased an additional 50,000 shares. Repurchases under the program may be made...

Notice of Plan to Voluntary Delist from Nasdaq and Deregister its Common Stock LOS ANGELES, Nov. 14, 2025 (GLOBE NEWSWIRE) — Taitron Components Incorporated (NASDAQ:TAIT) announces the Company will voluntarily delist its common stock from The Nasdaq Stock Market (“Nasdaq”) and, based upon ownership of its shares by fewer than 300 holders of record, deregister its common stock under the Securities Exchange Act of 1934 and suspend its public reporting obligations. Our Board of Directors concluded that the costs of maintaining the Nasdaq listing and remaining a public reporting company, including costs of compliance, the demands on management time and the Company resources required to maintain its listed and registered status, outweigh the benefits to the Company and its stockholders of continued Nasdaq listing and SEC reporting. The...

Third Quarter Net Sales and Adjusted EBITDA Exceeded Guidance Driven by 44% OEM GrowthGross Margin Expanded 710 Basis Points Year-over-YearRecent Public Offerings and Debt Restructuring Significantly Improve Financial PositionGuides to Fourth Quarter Net Sales of Approximately $13.0 Million Third Quarter 2025 Financial Highlights (All comparisons made are against the prior-year period)Net sales were $16.0 million, compared to $12.7 million, up 25.5%. OEM net sales were $10.7 million, compared to $7.4 million, up 44.3% Gross Margin was 29.7%, compared to 22.6%, up 710 basis points. Net Loss was $(11.1) million, compared to $(6.8) million. Adjusted EBITDA was $(2.1) million, compared to $(5.5) million.RENO, Nev., Nov. 14, 2025 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI),...

–   Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment regarding the study design of a Phase 3 program for VP-315 in basal cell carcinoma; Company presented new data on VP-315 at the recent Society for Immunotherapy of Cancer conference – – Received positive feedback from European Medicines Agency that supports a Marketing Authorization Application filing for YCANTH for molluscum without need for additional Phase 3 studies – – Received $10 million cash milestone payment for approval of YCANTH for molluscum in Japan – – Conference call scheduled for Monday, November 17, 2025, at 8:30 am ET – WEST CHESTER, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”)...

DALLAS, Nov. 14, 2025 (GLOBE NEWSWIRE) — Strive, Inc. (Nasdaq: ASST) (“Strive” or the “Company”), the first Bitcoin treasury company amplified exclusively with perpetual preferred equity, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights:Consummated the reverse acquisition of Asset Entities Inc. and concurrently raised $762.6 million through PIPE financing transaction and warrant exercises through September 30, 2025, with the opportunity to raise an additional $736.6 million through exercise of remaining warrants. Announced the entry into an agreement and plan of merger for the acquisition of Semler Scientific, Inc. (“Semler”) in an all-stock transaction that would result in Semler being a wholly owned subsidiary of Strive, subject to the satisfaction...